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Background: Recently, fibroblast growth factor receptor 1 (FGFR1) was discovered in squamous cell carcinomas (SCC) of the lung
with FGFR1 amplification described as a promising predictive marker for anti-FGFR inhibitor treatment. Only few data are
available regarding prevalence, prognostic significance and clinico-pathological characteristics of FGFR1-amplified and early-
stage non-small cell lung carcinomas (NSCLC). We therefore investigated the FGFR1 gene status in a large number of well-
characterised early-stage NSCLC.
Methods: FGFR1 gene status was evaluated using a commercially available fluorescent in situ hybridisation (FISH) probe on a
tissue microarray (TMA). This TMA harbours 329 resected, formalin-fixed and paraffin-embedded, nodal-negative NSCLC with a
UICC stage I–II. The FISH results were correlated with clinico-pathological features and overall survival (OS).
Results: The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly (Po0.0001) higher in squamous cell
carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%). Multivariate analysis revealed significantly
(P¼ 0.0367) worse 5-year OS in patients with an FGFR1-amplified NSCLC.
Conclusions: FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic
marker. Its potential role as a predictive marker for targeted therapies or adjuvant treatment needs further investigation.
Despite advances in diagnostics and treatment, lung cancer
remains the leading cause of cancer-related deaths worldwide. It
is estimated that 7% of the population will develop lung cancer
during their lifetime (Howlader et al, 2012). During the past
decade, the discovery of targetable oncogenic protein kinases, like
epidermal growth factor receptor (EGFR) mutations and anaplastic
lymphoma kinase (ALK) rearrangements (Shaw et al, 2013), have
revolutionised diagnosis and treatment of non-small cell lung
cancer (NSCLC) (Mok et al, 2009). However, predictive and
targetable oncogenic mutations have mainly been found in
adenocarcinomas (AC). The investigation of squamous cell
carcinomas (SCC) has lagged behind, with no approved targeted
drugs available thus far. Recently, several promising biological
pathways and genomic alterations have been identified in SCC of
the lung, including PIK3CA/AKT1, PTEN and fibroblast growth
factor receptor 1 (FGFR1) alterations (Weiss et al, 2010;
Hammerman et al, 2012). FGFR1 amplification is one of the most
promising findings in SCC due to the availability of FGFR1
inhibitors and its association with response to FGFR inhibitor
treatment, a result demonstrated in cell lines and xenograft mouse
models, respectively (Weiss et al, 2010; Zhang et al, 2012). The
FGFR1 gene belongs to the FGFR family of tyrosine kinase
receptors and is located on chromosome 8p11.23. The FGFR1
receptor is a transmembrane protein kinase (Thisse and Thisse,
2005). Binding of the ligand to the extracellular domain induces
dimerisation, auto-phosphorylation and activation of downstream
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pathways (Bae and Schlessinger, 2010). In this way FGFR1
contributes to cell proliferation, differentiation and migration
(Thisse and Thisse, 2005). Moreover, in vivo upregulation of
FGFR1 leads to cell transformation and carcinogenesis (Arbeit
et al, 1996). Recently, it was shown in cell cultures and in xenograft
mouse models that SCC harbouring FGFR1 amplifications respond
in up to 80% to anti-FGFR1 treatment (Weiss et al, 2010; Zhang
et al, 2012). Several small molecules targeting the FGFR1 tyrosine
kinase are now in clinical trials for the treatment of patients with
SCC of the lung and of other solid malignant tumours (Gavine
et al, 2012; Wolf et al, 2012). For most of these phase I and II
clinical trials, the inclusion criterion is the verification of FGFR1
amplification (ClinicalTrials.gov, 2013). Therefore, the assessment
of FGFR1 gene status might become increasingly important in the
future for patients with SCC of the lung.
As for EGFR- and ALK-targeted treatment, success of FGFR1
inhibitor treatment will be critically dependent on identification of
an appropriate predictive marker and its assessment. In this
context the knowledge of the prevalence of FGFR1 amplification
independent of treatment is crucial. Chemotherapy-naive patients
with early-stage NSCLC treated with surgery only are therefore
most suitable for evaluation of prognostic markers, as they are not
confounded by the effects of different previous therapies. In
addition, as about 30% of early-stage NSCLC relapse (El-Sherif
et al, 2006), a prognostic marker could help stratify patients who
might benefit from a more aggressive treatment.
Therefore, the aim of this study was to investigate the
prevalence, the clinico-pathological characteristics and the
prognostic significance of FGFR1 gene status in a large cohort of
early-stage NSCLC patients treated with surgery alone. The study
was performed according to the REMARK guidelines (McShane
et al, 2005).
MATERIAL AND METHODS
Patients. We searched for patients with early-stage (UICC stage
IA to IIB), node-negative NSCLC treated with curative surgery
only diagnosed at the Institute for Pathology, University Hospital
Basel, Switzerland and at the Institute for Pathology, University
Bern, Switzerland between January 1988 and August 2008.
Patients’ clinical and follow-up data were collected from hospital
charts and questionnaires sent to the primary-care physicians. This
retrospective study was approved by the ethical committee of Basel
(EKBB Nr. 31/12).
The staging work up for all patients before surgery was
performed according to institutional protocols including: history and
physical examination, routine laboratory evaluation, bronchoscopy,
chest/abdomen/pelvis computer tomography (CT) scan and bone
scintigraphy. In 2006, integrated whole-body PET–CT scan was
added for tumour staging and standardised intraoperative lymph
node staging was performed according to the ESTS guidelines
(Lardinois et al, 2006).
We identified 544 patients. Of those we excluded patients with
neo-adjuvant treatment (N: 39, 7.4%), non-informative fluorescent
in situ hybridisation (FISH) results (N: 92, 17%), rare lung cancer
histologies (N: 5, o1%), patients with a wedge resection (N: 5,
o1%) and with unknown surgical resection (N: 12, 2.2%), therefore
the final patient number was 329 (Figure 1). The remaining patient
cohort showed the expected prognosticators concerning age, gender,
T-category, stage and histology (data not shown). The cohort
included 244 (74.2%) male and 85 (25.8%) female patients. The
median age at the time of surgery was 66.9 years (range: 42–83
years) and the median survival time was 93.8 months (range:
67.3–115.8 months). The patients showed the following stage
distribution: 36 (11.0%) IA, 211 (64.1%) IB, 52 (15.8%) IIA and
30 (9.1%) IIB. A total of 239 (72.6%) patients had a smoking history
(active smokers: n¼ 156; ex-smokers: n¼ 83), 18 (5.5%) patients
were non-smokers and for 72 (21.9%) smoking history was not
available. The median number of pack years was 50 (range: 5–150).
The following distribution of histology was seen: 169 (51.4%) SCC,
137 (41.6%) AC and 23 (7.0%) large cell carcinoma (LC). The
surgery procedures included: 263 (80.0%) lobectomies, 41 (12.4%)
pneumonectomies and 25 (7.6%) bi-lobectomies. A complete
surgical resection (R0) was achieved in 325 (98.8%) patients and
an R1 status was diagnosed in 4 (1.2%) patients. The median
number of extirpated lymph nodes was 9.5 (range 1–65) and the
median tumour diameter was 40mm (range 5–170mm). The
following T-categories were recorded: 36 (10.9%) T1a, 211 (64.1%)
T1b, 52 (15.8%) T2a, 30 (9.1%) T2b and 0 (0%) T3. Adjuvant
chemotherapy was administered in 12 (4.2%) and adjuvant radio-
therapy in 6 (2.1%) patients (Table 1).
Specimen characteristics and tissue microarray (TMA). Paraffin-
embedded (FFPE) tissue samples fixed in 10% neutral-buffered
formalin were available for all the 329 patients from the archives of
the Institute for Pathology, University Hospital Basel, Switzerland
and at the Institute for Pathology, University Bern, Switzerland. For
the TMA construction, the best-preserved and most suitable tissue
samples were selected. One punch with a diameter of 0.6mm per
tumour was transferred from the donor tissue block to a receptor
paraffin block as previously described (Bubendorf et al, 2001).
Two pathologist specialised in pulmonary diseases (SS and MG)
reviewed all NSCLC for histology according to the current 2004
WHO recommendations. Staging was assigned according to the
TNM classification (7th Edition of the UICC TNM Staging
System).
Fluorescent in situ hybridisation. FGFR1 gene status was
evaluated using a commercially available FISH probe (FGFR1/
CEN8; ZytoVision, Bremerhaven, Germany). In this probe, the
FGFR1 gene locus (FGFR1) is labelled with a green fluorochrome
and the centromeric reference probe (CEN8) with an orange
fluorochrome. Before hybridisation, samples were cut to 5 mm
Case review
544 patients (Basel and Bern)
Tissue microarray construction
FGFR1 amplification status determined by FISH
Exclusion of neoadjuvantly treated patients (n =39),
those cases with unsuccessful FISH (n =92) and
〈〈minor〉〉 histology (n =5), those with wedge-resection
and unknown surgical resection (n =12)
396 Patients
329 Patients
Missing survival information (n =67)
Figure 1. Patients and sample selection flow chart. Study design. In a
first step, cases with stage I/II lung cancers of all histological subtypes
were identified retrospectively and re-reviewed. Representative tissue
blocks were selected and tissue microarray construction was
undertaken. Fluorescent in situ hybridisation for FGFR1 was carried out.
Patients with unsuccessful FGFR1 FISH, those with minor histologies
(i.e., other than adenocarcinomas, large cell carcinomas or squamous
cell carcinomas), neo-adjuvant-treated patients and patients with a
wedge resection and unknown surgical resection as well as patients
with missing survival data were excluded from the study. The final
cohort consisted of 329 patients.
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sections, deparaffinised and pretreated with commercial pre-
treatment kit Vysis (Abbott Molecular, Des Plaines, IL, USA).
Hybridisation was performed overnight in a humidified chamber
at 37 1C. Afterwards slides were washed with Vysis washing
solution and counterstained with Vysis DAPI (Abbott
Molecular). Amplification was defined as an FGFR1 to CEP8
signal ratio of X2.0. An example of an amplified SCC is shown
in Figure 2. The FGFR gene status was evaluated blinded from
clinical or pathological data.
Statistical considerations. Differences between FGFR1 gene
status and categorical clinico-pathological features were deter-
mined using the chi-square test or Fisher’s exact test, where
appropriate. Continuous variables such as tumour size were
analysed using the non-parametric Wilcoxon’s rank sum test.
Overall survival (OS; date of operation to date of death from any
cause or last date of follow-up) and disease-free survival (DFS;
date of operation to date of any sign of tumour relapse – local,
regional or distant) were the primary endpoints. Patients without
the event were censored at the date of last follow-up. Differences
in survival time were analysed using the log-rank or Wilcoxon’s
test and plotted using Kaplan–Meier curves. In addition, Cox
regression analysis in multivariable setting was employed to
determine the effect of FGFR1 gene status on survival time after
adjustment for possible confounding factors (smoking status,
tumour size and stage). Assumption of proportional hazards was
met. The hazard ratio (HR) and 95% CI were used in this setting
with a value of 1.0 considered baseline. P-values o0.05 were
considered statistically significant. All analyses were carried out
using SAS (V9.2; The SAS Institute, Cary, NC, USA).
Table 1. Clinico-pathological features and association FGFR1 gene status
FGFR1, N (%) (n¼329)
Feature
Freq analysis
group (n¼329)
Freq missing
group (n¼67) P-value
Negative,n¼288
(87.5%)
Amplified,n¼41
(12.5%) P-value
Age (years), median (range) 66.9 (42–83) 67.3 (38–82) 0.5231 66.9 (42–82) 67.9 (51.8–76.7) 0.9539
Tumour size (mm), median (range) 40 (5–170) 35 (10–105) 0.1015 35 (5–170) 45 (15–110) 0.0047a
Gender, n (%)
Female 85 (25.8) 15 (22.4) 0.5538 80 (94.1) 5 (5.9) 0.033
Male 244 (74.2) 52 (77.6) 208 (85.3) 36 (14.8)
Smoker, n (%)
Yes 239 (72.6) 24 (35.8) 0.8707 206 (86.2) 33 (13.8) 0.7472
No 18 (5.5) 1 (1.5) 17 (94.4) 1 (5.6)
No information 72 (21.9) 42 (62.7) 65 (90.3) 7 (9.7)
pT (UICC 7th) , n (%)
pT1 36 (10.9) 5 (7.5) 0.2807 36 (100.0) 0 (0.0) 0.0504
pT2 263 (80) 59 (88.0) 227 (86.3) 36 (13.7)
pT3 30 (9.1) 3 (4.5) 25 (83.3) 5 (16.7)
Stage UICC 7th, n (%)
Stage I 247 (75.1) 55 (82.1) 0.2188 224 (90.7) 23 (9.3) 0.0027
Stage II 82 (24.9) 12 (17.9) 64 (78.0) 18 (22.0)
Histology, n (%)
Adenocarcinoma 137 (41.6) 24 (35.8) 0.4961 134 (97.8) 3 (2.2) o0.0001
Large cell 23 (7) 7 (10.5) 20 (87.0) 3 (13.0)
Squamous cell 169 (51.4) 36 (53.7) 134 (79.3) 35 (20.7)
Operation, n (%)
Bilobectomy 25 (7.6) 5 (7.5) 0.1526 23 (92.0) 2 (8.0) 0.0003
Lobectomy 263 (80.0) 51 (76.1) 237 (90.1) 26 (9.9)
Pneumonectomy 41 (12.4) 10 (14.9) 28 (68.3) 13 (31.7)
Sublobar resection 0 (0.0) 1 (1.5)
Recurrence (n¼127)
No 58 (100.0) 0 — 53 (91.4) 5 (8.6) 0.1482
Yes 69 (100.0) 0 57 (82.6) 12 (17.4)
Overall survival (months) (n¼ 329),
median (95% CI)
93.8 (67.3–115.8) — — 103.1 (69.2–130.8) 43.9 (21.3-NE) 0.0205
Disease-free survival (months)
(n¼ 127), median (95% CI)
43.2 (34.6–73.1) — — 52.4 (38–123.1) 22.5 (8.7–60.7) 0.0466
Abbreviations: CI¼ confidence interval; UICC¼Union for International Cancer Control.
aSee also Result section for detailed information.
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RESULTS
FGFR1 amplification and clinico-pathological features. FGFR1
amplification was detected in 12.5% (41/329) of all NSCLC.
Amplification was detected in 20.7% (35/169) of SCC, 13% (3/23)
LC and 2.2% (3/137) AC. Hence, FGFR1 amplification was
significantly associated with SCC histology (Po0.0001).
No FGFR1 amplification was seen in T1 NSCLC (p3 cm; 0/36).
The remaining associations with FGFR1 amplification were as
follows: T2 (43 cm to o7 cm) 13.7% (36/263) and T3 (47 cm
tumour size) 16.7% (5/30). FGFR1 amplification was significantly
associated with a higher T-category (P¼ 0.0504) and larger tumour
size (P¼ 0.0047) (Table 1).
Stage I (IA and IB) NSCLC was amplified in 9.3% (23/247) and
stage II (IIA and IIB) in 22% (18/82), resulting in a significant
(P¼ 0.0027) correlation with higher tumour stage.
FGFR1 amplification was significantly more frequent in male
patients (14.8%; 36/244) compared with female patients (5.9%;
5/85) (P¼ 0.033). The prevalence of smoking history was higher in
males (76.3%) with a median of 50 pack-years (py; range:
5–150 py) compared with females (23.7%) with a median of
40 py (range: 15–100 py). FGFR1 amplification was seen in 13.8%
(33/239) of active smokers and in 5.6% (1/18) of non-smokers.
FGFR1 amplification and prognosis
Overall survival. Overall survival was available for all 329 patients
included in the analysis. Overall survival at 5 and 10 years were
significantly worse in patients with FGFR1 amplification
P¼ 0.0204 and P¼ 0.0205, respectively (Figure 3). All AC and
LC patients with FGFR1 amplification died within the first 5 years
resulting in a significantly (Po0.05) worse OS compared with
patients with a non-amplified tumour.
Disease-free survival. Information on tumour progression was
available in 38.6% (n¼ 127) of patients with the following
histologies: 46.5% (n¼ 59) SCC, 45.7% (n¼ 58) AC and 7.9%
(n¼ 10) LC. Patients with an FGFR1-amplified tumour showed a
significant difference in DFS at 5 years (P¼ 0.0466) compared with
patients with a non-amplified tumour and there was a trend
towards worse DFS in FGFR1-amplified tumours at 10 years
(P¼ 0.0965) with a median of 22.5 months (8.7–60.6) compared
with 52.4 months (38–123.1) in non-amplified tumours (95% CI).
Recurrence. Data for recurrence were available in 38.6% (n¼ 127)
patients. Of 17 amplified tumours with informative results, 12/17
(70.6%) had recurrence in comparison to 57/110 (51.8%)
non-amplified tumours with recurrence. The results are summarised
in Table 1.
Overall survival of SCC. Overall survival of patients with SCC
showed within the first 4 years significant worse survival compared
with patients with non-amplified tumour (2 years P¼ 0.024,
3 years P¼ 0.0208, 4 years P¼ 0.0422, 5 years P¼ 0.0685).
Multivariate analysis and prognosis. To control possible con-
founding factors, we included smoking status, tumour size and
pathological tumour stage in multivariate logistic regression
analysis. The multivariate analysis confirmed that FGFR1 ampli-
fication is an independent poor prognostic factor (P¼ 0.0367; HR:
2.06 (95% CI: 1.05–4.05)). Analysing FGFR1 status with tumour
size and histological subtype (squamous vs other) as independent
variables, tumour size shows only a marginal significant
Figure 2. Squamous cell carcinoma (SCC) with FGFR1 amplification. (A) Poorly differentiated SCC on the tissue microarray (haematoxylin and
eosin staining, original magnification  200). (B) Fluorescent in situ hybridisation of the same SCC shows FGFR1 amplification (FGFR1/CEP8 ratio:
42.0). The FGFR1 gene is labelled in green and the centromeric CEP8 reference probe in red. The full colour version of this figure is available at
British Journal of Cancer online.
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Figure 3. FGFR1 gene status and overall and progression-free survival.
(A) Patients (n¼329) with an FGFR1-amplified NSCLC show a
significantly worse OS at 5 (P¼0.0204) and 10 years (P¼0.0205)
(purple curve) compared with patients with a non-amplified NSCLC
(black curve). (B) Patients (n¼ 127) with FGFR1-amplified NSCLC
(purple curve) have worse disease-free survival at 5 years (P¼ 0.0466)
and 10 years (P¼0.00965) compared with patients with a non-
amplified NSCLC (black curve). The full colour version of this figure is
available at British Journal of Cancer online.
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relationship with amplification (P¼ 0.0854; OR (95% CI): 1.01
(0.99–1.03)), whereas histological subtype is significantly
associated with FGFR1 amplification (Po0.0001; OR (95% CI):
7.32 (2.77–19.3)). In a second analysis with smoking status and
tumour size, again a marginal significance for size was noticed
(P¼ 0.0763; OR (95% CI): 1.02 (0.99–1.04)), whereas smoking
status was not associated with FGFR1 amplification (P¼ 0.3890;
OR (95% CI): 2.5 (0.31–20.1)).
The results are shown in Table 2.
DISCUSSION
Different pathways are activated due to FGFR1 upregulation such
as, for example, mitogen-activated protein kinase (MAPK)
signalling (Weiss et al, 2010) a key pathway in carcinogenesis
and maintenance of lung cancer (Neuzillet et al, 2014). Therefore,
disruption of tumorigenesis by targeting this kinase cascade is of
great clinical value. A promising novel target is the tyrosine kinase
FGFR1, especially for FGFR1-amplified NSCLC. Information on
the prevalence of FGFR1 amplification in NSCLC and its
correlations with clinico-pathological features is important for
further clinical studies and was the subject of this study.
FGFR1 amplification detected by FISH is common in early-stage
SCC (20.7%) and in LC (13%) but rare in AC (2.2%). This finding
is in line with previous studies (Table 3). Not surprisingly, FGFR1
amplification was mostly seen in active smokers or ex-smokers of
male gender as most SCC are diagnosed in men with a smoking
history. Some studies assumed that FGFR1 might contribute to
carcinogenesis in SCC (Freier et al, 2007). Whether smoking causes
FGFR1 alterations or whether smoking and FGFR1 alterations are
independent and trigger combined tumorigenesis in NSCLC has to
be determined in further studies.
It is hypothesised that FGFR1 amplification is a driver mutation
(Weiss et al, 2010) and subsequently should therefore be seen early
on in small tumours. However, we were unable to see any FGFR1
amplification in small tumours (T1); therefore this hypothesis is
difficult to substantiate with our results. A possible explanation of
our results could be that FGFR1 amplification is acquired later
during tumour growth, which would explain why FGFR1
amplification was not detected in small tumours (T1). The
hypothesis of FGFR1 amplification as passenger mutation is
supported by the observation that the prevalence of FGFR1
amplification does increase with tumour size (T1: 0%, T2: 13.7%;
T3: 16.7%). It has previously been shown that FGFR1 amplification
can be focal (Heist et al, 2012; Tran et al 2013), resulting in
Table 2. Multivariate overall and disease-free survival analyses of FGFR1 gene status adjusting for smoking status, tumour size and TNM stage
All patients Squamous cell carcinoma patients
P-value HR (95% CI) P-value HR (95% CI)
Overall survival
FGFR1
Negative 0.0367 1 0.8668 1
Amplified 2.06 (1.05–4.05) 1.05 (0.57–1.93)
Smoking status
Non-smoker 0.3209 1 Not includeda
Smoker 1.68 (0.6–4.7)
Tumour size
Baseline 0.825 1 0.5829 1
1-unit increase 1.0 (0.98–1.02) 1.01 (0.99–1.02)
pT stage
pT1 0.781 1 0.8284 1
pT2 1.14 (0.44–2.95) 1.1 (0.48–2.48)
Disease-free survival
FGFR1
Negative 0.2539 1 0.7973 1
Amplified 1.46 (0.76–2.81) 1.12 (0.48–2.58)
Smoking status
Non-smoker Not includedb Not includeda
Smoker
Tumour size
Baseline 0.1666 1 0.0483 1.0 (1.03 (1.0–1.06)
1-unit increase 1.01 (0.99–1.04)
pT stage
pT1 0.1277 1 0.871 1.1 (0.34–3.61)
pT2 2.03 (0.82–5.0)
Abbreviations: CI¼ confidence interval; HR¼ hazard ration; TNM¼ tumour–nodes–metastasis.
aOnly 3 non-smokers and 96 smokers. No contribution to multivariate analysis possible.
bTo prevent over-fitting, smoking status was removed from the analysis. It was not associated with DFS in univariate analysis, whereas size and pT were.
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false-negative findings in T1 cancers using our TMA. This could be
true mainly for tumours with a small tumour-cell population with
FGFR1 amplification. However, such heterogeneity of FGFR1
amplification would apply for all stages and tumour sizes, and can
hardly explain the differences in FGFR1 amplification between
stages. A study addressing the issue of tumour heterogeneity and
tumour marker validation on TMAs advised four to five cores for
best results. However, accurate results of heterogeneously dis-
tributed tumour markers using TMAs are dependent on many
factors such as for example, complexity of the staining assessment
or the amount of positivity of a certain marker. Investigation of
larger patient cohorts helps in getting appropriate results (Goethals
et al, 2006). Interestingly, looking at studies using TMAs vs studies
using whole tissue sections (Table 3), both groups had similar
Table 3. Selected lung cancer studies analysing the FGFR1 gene status in lung cancer patients using FISH technique
Author
Number
of
NSCLC
analysed
Tissue
technique
FGFR1
amplifi-
cation
(%)
FGFR1
amplification
and
histology
ISH probe
used
Definition of
FGFR1amplification
Tumour
stages
included
in the
study
Overall
survival
whole
patient
cohort
Overall
survival early
stage (I and II)
Weiss
et al, 2010
153 TMA (two to
three cores)
22 only SCC
analysed
FGFR1 locus:
BAC
Reference:
none
FGFR1 49 signals IA, IB, IIB,
IIIA, IIIB
(available
from n¼ 15)
No data No data
Heist et al,
2012
226 Whole tissue
sections
16 only SCC
analysed
FGFR1 locus:
BAC
Reference:
commercially
available CEP8
Ratio FGFR1/CEPX2.2 IA; IB; IIA; IIB;
IIIA; IIIB; IV
No statistical
difference
between
FGFR1-
amplified and
non-amplified
No difference
between
FGFR1-
amplified and
non-amplified
(n¼ 155)
Kohler
et al, 2012
260 TMA (one
core)
6.5 10.5% SCC,
4.7% AC
Commercially
available dual-
colour FISH
probe
FGFR1X4 signals T1; T2; T3;
T4; N0; 4N0
No impact No data
Schildhaus
et al, 2012
407 Whole tissue
sections
17.3 20% SCC and 1x
ASCC and 1x LC
Commercially
available dual-
colour FISH
probe
FGFR1/CEN8 ratio X2.0
or average number of
FGFR1 signals per tumour
cell nucleus is X6 or the
percentage of tumour
cells containing X15
FGFR1 signals or large
clusters in X10% or the
percentage of tumour
cells containing X5
FGFR1 signals in X50%
No data No impact
(preliminary
data)
No data
Zhang
et al, 2012
127 Whole tissue
sections
8.7 12.5% SCC, 7%
AC
FGFR1 locus:
BAC
Reference:
commercially
available CEP8
Ratio FGFR1/CEPX2.0 or
X10%gene cluster
I, II, III, IV No data No data
Craddock
et al, 2013
121 TMA (three
cores)
18.2 only SCC
analysed
Commercially
available dual-
colour FISH
probe
45 Copies of FGFR1 IA, IB, IIA, IIB,
IIIA, IIIB, IV
No significant
difference
No data
Kim et al,
2013
262 TMA (three
cores)
13 Only SCC
analysed
Commercially
available dual-
colour FISH
probe
FGFR1 signal X9 (high-
level amplification)
I; II; IIIA; IIIB High-level
FGFR1
amplified
shorter survival
and DFS
No data
Tran et al,
2013
264 TMA (three
to six cores)
14 21.8% SCC,
20.5%LC, 5.2%
AC
Commercially
available dual-
colour FISH
probe
According to Schildhaus
et al, 2012
IA, IB, IIA, IIB,
III
FGFR1-
amplified
tumours better
prognosis
No data
Current
study
329 TMA (one
core)
12.5 20.7% SCC,
2.2% AC, 13%
LC
Commercially
available dual-
colour FISH
probe
FGFR1 to CEP8 signal
ratio of X2.0.
IA, IB, IIA, IIB Worse OS and
worse DFS
Difference
between
FGFR1-
amlified and
non-amplified
tumours
(n¼ 329)
Abbreviations: AC¼ adenocarcinoma; BAC¼bacterial artificial chromosome; FISH¼ fluorescent in situ hybridisation; LC¼ large cell carcinoma; NSCLC¼ non-small cell lung carcinoma;
SCC¼ squamous cell carcinoma; TMA¼ tissue microarray.
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ranges of FGFR1-amplified tumours (TMA: 6.5%–22% vs whole
tissue section: 8.7%–17.3%) indicating that TMAs can be suitable
to validate FGFR1 gene status on large patient samples. However,
some of the variability in the FGFR1 gene status seen between the
different studies might be explained as well by other factors such as
ethnicity. Hence, our result of 20.7% amplified SCC correlates best
with the Weiss study that included nearly the same ethnic group
(mostly Swiss patients) and showed 22% amplified SCC.
In our study, patients with an FGFR1-amplified NSCLC showed
a significantly worse 5-year (P¼ 0.0204) and long-term (10-year)
OS (P¼ 0.0205), more frequent recurrence (70.6% vs 51.8%) and
significantly shorter long-term DFS (P¼ 0.0466). These results
indicate that FGFR1 amplification is a negative prognostic marker
in early-stage NSCLC. However, it is still controversially discussed
whether FGFR1 amplification is associated with worse OS. Some
previous studies showed unfavourable prognosis (Kim et al, 2013),
some showed no difference (Heist et al, 2012; Craddock et al, 2013)
and some have concluded that FGFR1 amplification could be a
favourable prognostic marker (Tran et al, 2013). The reason for
this conflicting data might be the mixed patient cohorts including
early and advanced lung cancer patients and the different criteria
used to determine FGFR1 amplification (see Table 3). The one
study using similar cut-off criteria for FGFR1 amplification and
with available survival data on early-stage lung cancer patients
showed no significant difference in OS between patients with an
amplified and non-amplified tumour (Heist et al, 2012). However,
this study included only SCC lung cancer patients and it is not
known whether the cohort of early-stage lung cancer patients did
as well include neo-adjuvant-treated patients. As we analysed in
our cohort SCC lung cancers only, we could clearly see a
significantly worse OS of patients with an FGFR1-amplified
tumour within the first 4 years (Figure 4). After this time point
FGFR1 amplification had no prognostic significance in patients
with SCC lung cancer may be because all patients with an
aggressive, FGFR1-amplified tumour died early. This seems to be
true especially for AC and LC as these patients contributed
substantially to the significantly worse OS in our multivariate
analysis. Our study focused on a well-defined patient group of
node-negative early-stage NSCLC treated with surgery alone and
that might have resulted in a more accurate survival data. Reasons
for worse OS and worse DFS in patients with FGFR1-amplified
tumours could be due to the activation of proliferation as it was
shown in lung cancer cell lines (Weiss et al, 2010). This could
explain our finding that FGFR1-amplified tumours show a
significant higher T-category (P¼ 0.0504) and larger tumour size
(P¼ 0.0047). However, we do not have data on proliferation and
FGFR1 gene status to support this theory. We can, however,
conclude that FGFR1 amplification is an indicator of more
aggressive tumour biology and that patients with an FGFR1-
amplified tumour would need special treatment.
FGFR1 amplification is discussed as a possible new therapeutic
target for anti-FGFR1 inhibitors (Weiss et al, 2010); therefore, we
feel that FGFR1 amplification status should be evaluated prospec-
tively in patients with SCC lung cancer and LC, and might be as
well in AC. As patients with SCC lung cancer have only limited
options regarding systemic therapies, they might profit from a
targeted therapy. In this context it is also worth noting that FGFR1
gene status in primary and lymph node metastases are reported as
highly concordant (97.7%). Therefore, FGFR1 gene status might be
determined on both sites (Craddock et al, 2013). Whether FGFR1 is
not only involved in tumorigenesis but also might as well in
lymphatic spread has to be determined in further studies.
In a recently published study, it was shown that increased
expression of FGFR1 was observed in cell lines resistant to gefitinib
(Terai et al, 2013) and in another study it was observed that
patients with amplified FGFR1 status benefit from adjuvant
chemotherapy (Kim et al, 2013). These findings revealed further
the potential role of FGFR1 as a predictive marker not only for
anti-FGFR therapy but also might as well for other lung cancer
treatments.
In summary, we showed that FGFR1 amplification is a negative
prognostic marker in patients with early-stage NSCLC treated with
surgery. Moreover, our data challenged the hypothesis of FGFR1 as
a driver mutation as we were not able to detect any FGFR1
amplification in small tumours (T1). These findings may be of
value when planning future prospective or translational studies on
FGFR1 and NSCLC. However, we have to consider that our results
are based on retrospective data, and clinical data of recurrence
or tumour progression were not available for all patients.
A disadvantage of our study is that some of the patients with
surgery before 2006 had only limited lymph node staging as
standardisation of intraoperative lymph node staging was intro-
duced in 2006 (Lardinois et al, 2006). Using a TMA with only one
core per tumour can be limiting, and we might have missed some
of the tumours with a heterogeneous FGFR1 amplification.
As discussed, however, we feel strongly that our assessment of
FGFR1 gene status in this large cohort is accurate.
To conclude, FGFR1 amplification is frequent in early-stage
NSCLC, especially in SCC, and it appears to be a marker of poor
clinical outcome in these patients. Whether it can be used as a
prognostic marker has to be elucidated in further clinical studies.
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